Exploring 3 Undervalued Small Caps With Insider Buying Across Global Markets

As global markets experience a rebound, with major U.S. stock indexes climbing higher amid easing core inflation and strong bank earnings, small-cap stocks are capturing attention as they ride the wave of broader market optimism. In this dynamic environment, identifying promising small-cap companies often involves examining factors like insider buying activity, which can signal confidence in a company's potential growth prospects despite current economic uncertainties.

Top 10 Undervalued Small Caps With Insider Buying

Name	PE	PS	Discount to Fair Value	Value Rating
4imprint Group	17.4x	1.4x	32.44%	★★★★★☆
Maharashtra Seamless	9.6x	1.7x	38.91%	★★★★★☆
Speedy Hire	NA	0.3x	31.87%	★★★★★☆
Robert Walters	33.7x	0.2x	32.56%	★★★★☆☆
Logistri Fastighets	12.2x	8.6x	42.75%	★★★★☆☆
CVS Group	26.5x	1.1x	46.23%	★★★★☆☆
Mark Dynamics Indonesia	13.0x	4.2x	6.95%	★★★☆☆☆
Paradeep Phosphates	28.4x	0.9x	18.18%	★★★☆☆☆
THG	NA	0.3x	-512.81%	★★★☆☆☆
Digital Mediatama Maxima	NA	1.3x	12.52%	★★★☆☆☆

Click here to see the full list of 189 stocks from our Undervalued Small Caps With Insider Buying screener.

Let's explore several standout options from the results in the screener.

UIE (CPSE:UIE)

Simply Wall St Value Rating: ★★★★☆☆

Overview: UIE is an investment holding company primarily engaged in the agro-industrial sector through its significant ownership in United Plantations Berhad, with a focus on palm oil and coconut production.

Operations: The company's revenue primarily comes from United Plantations Berhad, with recent figures showing $462.25 million in revenue. The gross profit margin has shown a noticeable upward trend, reaching 78.82% in the latest period. Operating expenses have been consistently managed around $121-130 million recently, contributing to a net income margin of 34.82%.

PE: 8.4x

UIE's recent earnings report highlights its dynamic growth, with third-quarter sales reaching US$128.52 million, up from US$115.36 million the previous year, and a net income of US$32.2 million compared to a prior loss of US$18.43 million. Despite relying entirely on external borrowing for funding, insider confidence is evident with purchases throughout 2024. The company's strong earnings per share increase from USD 1.01 to USD 2.57 over nine months suggests potential in the small-cap sector amidst their industry challenges and opportunities for growth ahead.

• Delve into the full analysis valuation report here for a deeper understanding of UIE.

• Evaluate UIE's historical performance by accessing our past performance report.

AMG Critical Materials (ENXTAM:AMG)

Simply Wall St Value Rating: ★★★★☆☆

Overview: AMG Critical Materials operates in the production and supply of specialty metals and materials, with a market cap of approximately €1.67 billion.

Operations: AMG Critical Materials generates revenue primarily through its sales, with recent figures indicating a decline in gross profit margin from 29.37% to 16.62%. The company's cost of goods sold (COGS) has been a significant component of expenses, contributing to fluctuations in net income margins over time. Operating expenses, including general and administrative costs, also play a crucial role in the financial outcomes observed across different periods.

PE: -11.5x

AMG Critical Materials, a smaller company in the materials sector, recently reported a challenging financial period with a net loss of US$13.35 million for Q3 2024 and US$40.62 million over nine months. Despite this, earnings are projected to grow by 110% annually. Insider confidence is evident as insiders have been purchasing shares throughout the past year. However, high volatility in share price and reliance on external borrowing present risks. The company's future prospects hinge on stabilizing its financial position while capitalizing on growth potential.

• Dive into the specifics of AMG Critical Materials here with our thorough valuation report.

• Assess AMG Critical Materials' past performance with our detailed historical performance reports.

AddLife (OM:ALIF B)

Simply Wall St Value Rating: ★★★★★☆

Overview: AddLife is a Swedish company that operates in the healthcare sector, focusing on the distribution and sale of products within its Labtech and Medtech segments, with a market cap of SEK 12.34 billion.

Operations: Labtech and Medtech segments are the primary revenue streams, contributing SEK 3.71 billion and SEK 6.32 billion respectively. The gross profit margin has shown a varied trend, reaching 37.31% in the latest period. Operating expenses have consistently been a significant part of costs, with sales and marketing being the largest component within these expenses.

PE: 150.5x

AddLife, a smaller company in the market, has seen insider confidence with Håkan Roos increasing their stake by 9.75% in October 2024 through a transaction valued at SEK 31.8 million. Despite facing challenges like lower profit margins this year (1.2% down from 3.1%) and reliance on higher-risk external funding, earnings are forecasted to grow by over 50% annually. Recent sales figures show modest growth with SEK 7,468 million for nine months ending September 2024 compared to the previous year’s SEK 7,141 million.

• Get an in-depth perspective on AddLife's performance by reading our valuation report here.

• Gain insights into AddLife's historical performance by reviewing our past performance report.

Make It Happen

• Navigate through the entire inventory of 189 Undervalued Small Caps With Insider Buying here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com